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The Centers for Disease Control and Prevention (CDC) began an ongoing 
collaboration with the Ministry of Health (MoH) of Burkina Faso in 1991 to provide guidance 
for polio eradication. This cooperation has since expanded to include other important 
health issues. Most recently, CDC has focused on strengthening the country’s public health 
system by introducing and evaluating new vaccines, and continuing to work toward polio 
eradication and measles elimination.   
CDC works closely with partners in Burkina Faso, including the World Health Organization 




Polio and Measles 
CDC provides technical support to Burkina Faso for polio eradication and measles 
elimination activities. In 2009 Burkina Faso experienced its largest measles outbreak on 
record with more than 50,000 reported cases. CDC provided assistance with the outbreak 
epidemiology and later helped to design and implement studies to investigate the risk 
factors associated with contracting measles during the outbreak. CDC has also offered to 
provide technical assistance for a November 2014 campaign in Burkina Faso to introduce 
combined measles-rubella vaccine. 
Although wild poliovirus has not been detected in Burkina Faso since October 2009, the 
country is considered at moderate risk for polio based on immunization rates, surveillance, 
and proximity to countries with recent outbreaks (Cote d'Ivoire, Mali, and Niger).  Burkina 
Faso continues to conduct preventive nationwide polio vaccination campaigns to maintain 
the immunity of its population under 5 years old. For recent nationwide polio vaccination 
campaigns, CDC provided assistance with the planning, implementation, and supervision of 
campaign activities. 
Although CDC does not maintain an office in Burkina Faso, CDC employee Jim Ting is 
detailed to the immunization team in the WHO sub-regional office based in Ouagadougou 
and CDC funds a national surveillance officer through the WHO cooperative agreement (co-
ag). In addition, STOP polio teams rotate through Burkina Faso regularly. 
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At a Glance  
Population: 17,886,000 
Per capita income: $1,560 
Life expectancy at birth 
women/men: 57/56 yrs 
Under 5 mortality: 70/1000 
live births 
Source: Population Reference Bureau Fact 
Sheet, 2014 
 
Top 10 Causes of Death 
1. Malaria 22% 
2. Lower Respiratory 
Infections 13% 
3. Diarrheal Disease 12% 
4. Meningitis 5% 
5. HIV 3% 




8. Road Injuries 3% 
9. Stroke 3% 
10. Sepsis 2% 














Rotavirus Surveillance  
CDC works collaboratively with the MoH and WHO to support the development and 
implementation of hospital-based sentinel site surveillance in Burkina Faso for 
rotavirus. Since December 2013, Burkina Faso has intensified efforts to implement 
rotavirus surveillance. Four surveillance sites are now functioning and enrolling 
patients.  
Meningitis 
CDC’s Meningitis and Vaccine Preventable Diseases Branch (MVPDB) collaborates with 
the MoH and partners on strengthening capacities for meningitis surveillance, vaccine 
effectiveness and impact evaluation. In addition to approximately $200,000 provided 
annually to the MoH via a DLM-MoH/CDC memorandum of agreement, funds are 
available from the CDC/WHO regional co-ag to support meningitis activities in Burkina 
Faso. In addition, CDC provides equipment and consumables to the national laboratory. 
In 2010, a new meningococcal serogroup A conjugate vaccine (MenAfriVac), was 
introduced countrywide targeting more than 11 million people 1 to 29 years old.  
Surveillance data from Burkina Faso demonstrated a substantial immediate impact on 
the disease with no cases of serogroup A meningococcal meningitis occurring among 
vaccinated people in Burkina Faso. However, further data are required to assess 
MenAfriVac’s long-term impact and to evaluate the need for and effectiveness of future 
vaccines.  MVPDB is committed to continued collaboration with Burkina Faso in 
building and sustaining capacity for disease surveillance.  MenAfriNet is a Bill and 
Melinda Gates Foundation funded project to evaluate the impact of MenAfriVac throughout Africa’s meningitis belt, 
including Burkina Faso. Future plans for Burkina Faso include implementation of MenAfriNet, to guide research on new 
vaccines and strategies to optimize the impact of existing vaccines. 
Pneumococcal conjugate vaccine was introduced in Burkina Faso in 2013 to prevent meningitis.  CDC is supporting ongoing 
studies evaluating the effectiveness of the vaccine and implementation of a laboratory assay used to serotype Streptococcus 
pneumonia. 
Field Epidemiology and Laboratory Training Program (FELTP) 
In collaboration with the MoH of the eight French-speaking countries of West Africa and the University of Ouagadougou, 
CDC, through funding from the World Bank, is planning to re-launch and expand the West Africa Field Epidemiology and 
Laboratory Training Program (WAFELTP), which began in 2010. This regional FELTP based in Ouagadougou will enroll 
residents from Benin, Burkina Faso, Côte d’Ivoire, Guinea, Mali, Niger, Senegal and Togo. The two-year training and service 
program is modeled after CDC’s Epidemic Intelligence Service , is designed for health professionals in entry- or mid-level 
positions, and is intended to build their capacity in applied epidemiology, surveillance, and enhanced public health practice. 
The World Bank, via WHO and the CDC Foundation, has provided $2.5 million for a period of three years for the WAFELTP.  
During the project period--ending December 2017--the program is expected to enroll two cohorts of 15 residents each. 
Impact in 
Burkina Faso 
 Burkina Faso was the second 
country in the African region 
region to introduce Rotateq 
vaccine for Rotavirus. 
 17 million doses of polio 
vaccine and 2.4 million doses 
of measles vaccine were given 
to children under 5 years old. 
 The last wild poliovirus case 
was detected in 2009. 
 More than 12 million people 
have been vaccinated against 
meningitis. 
 
For more information please contact Centers for Disease Control and Prevention: 
CDC-Atlanta  
1600 Clifton Road NE, Atlanta, GA 30333  
Email: cgh@cdc.gov  
Web: http://www.cdc.gov/global     
 
  
    
 
For more country information:  http://www.cdc.gov/globalhealth/countries/burkinafaso 
